Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuzistra XR
- Development stage
- Unknown
- Lead developer
- Vernalis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tuzistra XR is an extended-release oral suspension combining codeine polistirex (an opiate agonist antitussive) and chlorpheniramine polistirex (a histamine-1 receptor antagonist). It is indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults aged 18 years and older. **Mechanism of Action**: Codeine acts centrally on the cough center, while chlorpheniramine prevents histamine-mediated effects like capillary dilation and edema of the respiratory mucosa.
- Brand names
- Tuzistra XR
- Other names
- Chlorpheniramine Polistirex/Codeine Polistirex
02
Targets
HRH1 (Histamine H1 Receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Tuzistra XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tuzistra XR.